Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
C. Larrue, S. Mouche, P. Angelino…·J. Tamburini
The paper identifies ferritinophagy as a therapeutic target in quiescent leukemic stem cells, showing that inhibiting NCOA4 reduces leukemia.
V. Dembitz, H. Lawson, R. Burt…·P. Gallipoli
SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.
M. Sabatier, R. Birsen, J. Tamburini, J.-E. Sarry
This study identifies C/EBPα's role in promoting lipid anabolism and vulnerability to lipid oxidative stress in FLT3-mutant AML through regulation of the FASN-SCD axis.
S. Lin, C. Larrue, B. K. A. Seong…·K. Stegmaier
This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.
C. Bosc, N. Gadaud, A. Bousard…·J.-E. Sarry
This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.
C. Larrue, N. Guiraud, P.-L. Mouchel…·J.-E. Sarry
The paper identifies the ADM-CALCRL axis as a driver of drug-tolerant AML cells that persist after chemotherapy and proposes it as a therapeutic target to prevent relapse.